Navigation Links
Misonix Announces New Distribution Agreement for India
Date:11/14/2011

FARMINGDALE, N.Y., Nov. 14, 2011 /PRNewswire/ --- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic and other surgical and medical applications, has entered into a new, four year, exclusive distribution agreement with Cure Surgicals, based in New Delhi, India, for the distribution of the SonaStar® Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone Cutter. The agreement provides Cure Surgicals with the right to sell throughout India. Included in the agreement are annual minimum purchase requirements.  Initial product training is complete and open market sales have begun.

Cure Surgicals has successful experience with launching state-of-the-art products and, in conjunction with Misonix, has begun holding physician training sessions throughout India aimed at acquainting the clinical community with the Company's unique technology.  Three of these meetings have been held to date, all in major cities, with more than 75 surgeons in attendance.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

"Misonix is excited to have Cure Surgicals representing our products in this large and important South Asian market.  Their reputation as an aggressive distributor of advanced medical devices in India is well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Their approach to educating the Indian clinical community as to the value of therapeutic ultrasound technology mirrors that of Mixonix in other key markets..  We are particularly pleased that they will be selling two of our key products through their well established distribution network in India."

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Reports a 14.8% Increase in Revenue for the First Quarter Fiscal 2012 Financial Results
2. Misonix Schedules First Quarter Fiscal 2012 Financial Results Conference Call; November 9, 2011 at 4:30 p.m. Eastern
3. Misonix Announces its Exhibition at the European Association of Neurosurgical Societies
4. Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care
5. Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques
6. Misonix Announces New Distribution Agreement for Austria, Germany & Switzerland
7. Misonix Announces the Sale of Its Laboratory and Forensic Safety Products Business for $1.5 Million
8. Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results
9. Misonix Schedules Fourth Quarter and Year-End Fiscal 2011 Financial Results Conference Call; September 20, 2011 at 4:30 p.m. Eastern
10. Misonix Announces New Distribution Agreement for Australia and New Zealand
11. Misonix Announces Entry Into Surgical Wound Debridement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
(Date:12/2/2016)... YORK , December 2, 2016 ... of its past losses following Trump,s victory early in ... potential, and fund managers are now predicting an uptick ... at four equities to see how they have fared ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, known ... Medicare beneficiaries who are looking to switch from their current plan to a Medicare ... during this period order for their new policy to go into effect in 2017. ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to announce ... covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients ... life 6 years in the last 3 decades,” says Dr. Valentine Fuster, a ...
Breaking Medicine News(10 mins):